At INTERCEPT, we are transforming the landscape of Crohn’s disease research by shifting from reactive symptom management to proactive early detection and prevention by using biomarkers to identify individuals at risk before symptoms develop, making diagnosis earlier than early. In other words, the aim is to stop Crohn’s disease. MOLGENIS leads the data infrastructure work package. This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194780.